Table Of Contents

1. Introduction 12
1.1. Objectives Of The Study 12
1.2. Market Definition 12
1.3. Overview Of U.S. Hla Typing Transplant Diagnostics Services Market 12
1.4. Currency And Pricing 13
1.5. Limitation 13
1.6. Markets Covered 14
2. Market Segmentation 15
2.1. Markets Covered 15
2.2. Years Considered For The Study 16
2.3. Currency And Pricing 16
2.4. Research Methodology 17
2.5. Primary Interviews With Key Opinion Leaders 20
2.6. Secondary Sources 21
2.7. Assumptions 21
3. Executive Summary 22
4. Market Overview 24
4.1. Drivers 26
4.1.1. Technological Advancements In Hla Typing 26
4.1.2. Increasing Number Of Solid Organ And Stem Cell Transplantation Procedures 26
4.1.3. Increased Research Grants, Funds, And Public-Private Investments 27
?
4.2. Restraints 28
4.2.1. Weak Reimbursements For Organ Donation And Transplantation Procedures 28
4.2.2. Expensive Ngs And Pcr-Based Devices 28
4.3. Opportunities 29
4.3.1. Rising Healthcare Infrastructure In Emerging Nations 29
4.4. Challenges 30
4.4.1. Significant Gap Between Number Of Organs Donated And Organs Required Annually 30
4.4.2. Lack Of Trained Staff 31
5. Premium Insights 32
6. U.S. Hla Typing Transplant Diagnostics Services Market,
By Technology 34
6.1. Overview 35
6.2. Next-Generation Sequencing (Ngs) 36
6.3. Polymerase Chain Reaction (Pcr) 37
6.3.1. Pcr Ssop (Sequence-Specific Oligonucleotide) 38
6.3.2. Pcr Ssp (Sequence-Specific Primer) 38
6.3.3. Pcr-Sbt (Sequencing Based Typing) 38
7. U.S. Hla Typing Transplant Diagnostics Services Market,
By End-Users 39
7.1. Overview 40
7.2. Specialty Clinics 41
7.3. Hospitals 41
7.4. Transplant Centers 41
7.5. Academic Institutes 42
?
8. U.S. Hla Typing Transplant Diagnostics Services Market, Company Landscape 43
8.1. Company Share Analysis; U.S. 43
9. Company Profiles 44
9.1. Proimmune Ltd. 44
9.1.1. Company Overview 44
9.1.2. Proimmune Ltd.; Company Snapshot 44
9.1.3. Product Portfolio 45
9.1.4. Recent Developments 45
9.2. Creative Biolabs 46
9.2.1. Company Overview 46
9.2.2. Creative Biolabs; Company Snapshot 46
9.2.3. Product Portfolio 46
9.2.4. Recent Developments 46
9.3. Histogenetics Llc 47
9.3.1. Company Overview 47
9.3.2. Histogenetics Llc; Company Snapshot 47
9.3.3. Product Portfolio 47
9.3.4. Recent Developments 47
9.4. The Ucla Immunogenetics Center 48
9.4.1. Company Overview 48
9.4.2. The Ucla Immunogenetics Center; Company Snapshot 48
9.4.3. Product Portfolio 48
9.4.4. Recent Developments 48
9.5. Admera Health 49
9.5.1. Company Overview 49
9.5.2. Admera Health; Company Snapshot 49
9.5.3. Product Portfolio 50
9.5.4. Recent Developments 50
9.6. Quick Biology 51
9.6.1. Company Overview 51
9.6.2. Quick Biology; Company Snapshot 51
9.6.3. Product Portfolio 51
9.6.4. Recent Developments 51
9.7. New York Blood Center 52
9.7.1. Company Overview 52
9.7.2. New York Blood Center; Company Snapshot 52
9.7.3. Product Portfolio 52
9.7.4. Recent Developments 52
9.8. The Sequencing Center 53
9.8.1. Company Overview 53
9.8.2. The Sequencing Center; Company Snapshot 53
9.8.3. Product Portfolio 54
9.8.4. Recent Developments 54
9.9. Bloodcenter Of Wisconsin 55
9.9.1. Company Overview 55
9.9.2. Bloodcenter Of Wisconsin; Company Snapshot 55
9.9.3. Product Portfolio 55
9.9.4. Recent Developments 55
9.10. Laboratory Corporation Of America Holdings 56
9.10.1. Company Overview 56
9.10.2. Laboratory Corporation Of America Holdings; Revenue Analysis 56
9.10.3. Product Portfolio 57
9.10.4. Recent Developments 57
?
9.11. Thermo Fisher Scientific Inc. 58
9.11.1. Company Overview 58
9.11.2. Thermo Fisher Scientific Inc. ;Revenue Analysis 58
9.11.3. Product Portfolio 59
9.11.4. Recent Developments 59
10. Related Reports 60